Cargando…

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be particularly complex. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new optio...

Descripción completa

Detalles Bibliográficos
Autores principales: Nijhof, Inger S., van de Donk, Niels W. C. J., Zweegman, Sonja, Lokhorst, Henk M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756574/
https://www.ncbi.nlm.nih.gov/pubmed/29188449
http://dx.doi.org/10.1007/s40265-017-0841-y
_version_ 1783290745712541696
author Nijhof, Inger S.
van de Donk, Niels W. C. J.
Zweegman, Sonja
Lokhorst, Henk M.
author_facet Nijhof, Inger S.
van de Donk, Niels W. C. J.
Zweegman, Sonja
Lokhorst, Henk M.
author_sort Nijhof, Inger S.
collection PubMed
description Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be particularly complex. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new options are currently available for the treatment of relapsed multiple myeloma, including recently approved drugs, such as the second- and third-generation proteasome inhibitors carfilzomib and ixazomib, the immunomodulatory agent pomalidomide, the monoclonal antibodies daratumumab and elotuzumab and the histone deacetylase inhibitor panobinostat, but also new targeted agents are under active investigation (e.g. signal transduction modulators, kinesin spindle protein inhibitors, and inhibitors of NF-kB, MAPK, AKT). We here describe a new paradigm for the treatment of relapsed multiple myeloma. The final goal should be finding a balance among efficacy, toxicity, and cost and, at the end of the road, achieving long-lasting control of the disease and eventually even cure in a subset of patients.
format Online
Article
Text
id pubmed-5756574
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-57565742018-01-22 Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update Nijhof, Inger S. van de Donk, Niels W. C. J. Zweegman, Sonja Lokhorst, Henk M. Drugs Review Article Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be particularly complex. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new options are currently available for the treatment of relapsed multiple myeloma, including recently approved drugs, such as the second- and third-generation proteasome inhibitors carfilzomib and ixazomib, the immunomodulatory agent pomalidomide, the monoclonal antibodies daratumumab and elotuzumab and the histone deacetylase inhibitor panobinostat, but also new targeted agents are under active investigation (e.g. signal transduction modulators, kinesin spindle protein inhibitors, and inhibitors of NF-kB, MAPK, AKT). We here describe a new paradigm for the treatment of relapsed multiple myeloma. The final goal should be finding a balance among efficacy, toxicity, and cost and, at the end of the road, achieving long-lasting control of the disease and eventually even cure in a subset of patients. Springer International Publishing 2017-11-29 2018 /pmc/articles/PMC5756574/ /pubmed/29188449 http://dx.doi.org/10.1007/s40265-017-0841-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Nijhof, Inger S.
van de Donk, Niels W. C. J.
Zweegman, Sonja
Lokhorst, Henk M.
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
title Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
title_full Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
title_fullStr Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
title_full_unstemmed Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
title_short Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
title_sort current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756574/
https://www.ncbi.nlm.nih.gov/pubmed/29188449
http://dx.doi.org/10.1007/s40265-017-0841-y
work_keys_str_mv AT nijhofingers currentandnewtherapeuticstrategiesforrelapsedandrefractorymultiplemyelomaanupdate
AT vandedonknielswcj currentandnewtherapeuticstrategiesforrelapsedandrefractorymultiplemyelomaanupdate
AT zweegmansonja currentandnewtherapeuticstrategiesforrelapsedandrefractorymultiplemyelomaanupdate
AT lokhorsthenkm currentandnewtherapeuticstrategiesforrelapsedandrefractorymultiplemyelomaanupdate